NEJM August 2026 In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

This study evaluates the clinical effectiveness of VERVE-102, a novel gene-editing treatment designed to combat high cholesterol by permanently altering a specific liver protein. By utilizing lipid nanoparticlesto deliver a molecular editor, the therapy seeks to mimic a natural genetic mutation that protects against cardiovascular disease. The phase 1 trial results demonstrate that a single infusion can lead to a significant and long-lasting reduction in both the PCSK9 protein and harmful LDL cholesterol levels. Ultimately, the research suggests that targeted base editing serves as a safe and durable alternative to traditional daily medications for managing hereditary heart risks.